Literature DB >> 28743566

Mortality prediction in patients with acute kidney injury requiring renal replacement therapy after cardiac surgery.

Inga Skarupskienė1, Dalia Adukauskienė2, Jurgita Kuzminskienė1, Laima Rimkutė3, Vilma Balčiuvienė4, Edita Žiginskienė1, Vytautas Kuzminskis1, Agnė Adukauskaitė5, Daiva Pentiokinienė6, Inga Arūnė Bumblytė1.   

Abstract

BACKGROUND AND
OBJECTIVE: Acute kidney injury (AKI) is a common and potentially serious postoperative complication after cardiac surgery, and it remains a cause of major morbidity and mortality. The aim of our study was to assess the prognostic illness severity score and to estimate the significant risk factors for poor outcome of patients with AKI requiring renal replacement therapy (RRT) after cardiac surgery.
MATERIALS AND METHODS: We retrospectively analyzed data of adult (>18 years) patients (n=111) who underwent open heart surgery and had developed AKI with need for RRT. Prognostic illness severity scores were calculated and perioperative risk factors of lethal outcome were assessed at the RRT initiation time. We defined three illness severity scores: Acute Physiology and Chronic Health Evaluation (APACHE II) as a general score, Sequential Organ Failure Assessment (SOFA) as an organ failure score, and Liano score as a kidney-specific disease severity score. Logistic regression was also used for the multivariate analysis of mortality risk factors.
RESULTS: Hospital mortality was 76.5%. More than 7% of patients remained dialysis-dependent after their discharge from the hospital. The prognostic abilities of the scores were assessed for their discriminatory power. The area under the receiver-operating characteristic (ROC) curve of SOFA score was 0.719 (95% CI, 0.598-0.841), of Liano was 0.661 (95% CI, 0.535-0.787) and 0.668 (95% CI, 0.550-0.785) of APACHE II scores. From 16 variables analyzed for model selection, we reached a final logistic regression model, which demonstrated four variables significantly associated with patients' mortality. Glasgow coma score<14 points (OR=3.304; 95% CI, 1.130-9.662; P=0.003), mean arterial blood pressure (MAP)<63.5mmHg (OR=3.872; 95% CI, 1.011-13.616; P=0.035), serum creatinine>108.5μmol/L (OR=0.347; 95% CI, 0.123-0.998; P=0.046) and platelet count<115×109/L (OR=3.731; 95% CI, 1.259-11.054; P=0.018) were independent risk factors for poor patient outcome.
CONCLUSIONS: Our study demonstrated that SOFA score estimation is the most accurate to predict the fatal outcome in patients with AKI requiring RRT after cardiac surgery. Lethal patient outcome is related to Glasgow coma score, mean arterial blood pressure, preoperative serum creatinine and postoperative platelet count.
Copyright © 2017 The Lithuanian University of Health Sciences. Production and hosting by Elsevier Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Cardiac surgery; Mortality prediction; Renal replacement therapy

Mesh:

Year:  2017        PMID: 28743566     DOI: 10.1016/j.medici.2017.06.003

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  3 in total

1.  Application of interpretable machine learning for early prediction of prognosis in acute kidney injury.

Authors:  Chang Hu; Qing Tan; Qinran Zhang; Yiming Li; Fengyun Wang; Xiufen Zou; Zhiyong Peng
Journal:  Comput Struct Biotechnol J       Date:  2022-06-03       Impact factor: 6.155

2.  Prolonged use of noninvasive positive pressure ventilation after extubation among patients in the intensive care unit following cardiac surgery: The predictors and its impact on patient outcome.

Authors:  Pei-Ku Chen; Chun-Che Shih; Fang-Chi Lin; Diahn-Warng Perng; Kun-Ta Chou; Yu Ru Kou; Hsin-Kuo Ko
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

3.  Red Cell Distribution Width as a Severity Marker on the Outcome of Patients with Acute Kidney Injury on Renal Replacement Therapy.

Authors:  Sunil Nanjarapalle; Aloka Samantaray; Sivakumar Vishnubhotla
Journal:  Indian J Crit Care Med       Date:  2020-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.